ICF: kEtamine for the treatment of DEpression with anorexia Nervosa (EDEN)

ICF：kEtamine 用于治疗抑郁症伴神经性厌食症 (EDEN)

• 批准号: MR/Y019504/1
• 负责人: Hubertus Himmerich
• 金额: $ 193.32万
• 依托单位: King's College London
• 依托单位国家: 英国
• 项目类别: Research Grant
• 财政年份: 2024
• 资助国家: 英国
• 起止时间: 2024 至 无数据
• 项目状态: 未结题
• 来源: https://gtr.ukri.org/projects?ref=MR%2FY019504%2F1
• 关键词: ICF; kEtamine; treatment; DEpression; anorexia

Anorexia nervosa is a restrictive eating disorder that has a high rate of death. Approximately a third of people develop a persisting form of illness, which is often accompanied by depression, which is a barrier to recovery. Anti-depressant medications are not effective in treating depression in patients with chronic anorexia and new treatments are needed.Ketamine is currently used for the treatment of depression in the UK and may be effective in patients with AN and additional depression. The hope for this study is that people with both, anorexia, and depression, will experience relief from depression and thus get back their hope for improvement, motivation, and strength to fight their anorexia.The EDEN project aims to investigate the effect of ketamine in alleviating depression in 60 adults with a diagnosis of persisting anorexia and treatment-resistant depression. Participants in the study will randomly receive either ketamine, or a dummy pill, twice a week for a total of six months. To verify that the drug is tolerable, the first four doses will be given in the Clinical Research Facility at King's College London, where participants will be monitored by medical professionals. After this point, and if the drug is tolerated well, participants can take the drug home. All participants will also receive ten "psychoeducation and integration" sessions which are designed to increase the beneficial effects of ketamine. The main outcome will be looking at whether a sufficient number of people were recruited into the study and did not drop out over the duration of the study period, and whether people found the drug, as well as taking part in the study itself, acceptable. Measurements of depression, anorexia symptoms, suicidality, and quality of life will be taken after 28 days, and 3-, 6- and 7 months. Blood samples will also be taken in order to look at levels of ketamine.

神经性厌食症是一种限制性饮食失调症，死亡率很高。大约三分之一的人会发展出一种持续的疾病形式，这种疾病通常伴随着抑郁症，这是康复的障碍。抗抑郁药在治疗慢性厌食症患者的抑郁症中无效，需要新的治疗方法。目前使用酮胺治疗英国的抑郁症，可能对患有AN和其他抑郁症患者有效。这项研究的希望是，患有厌食症和抑郁症的人会缓解抑郁症，从而恢复对厌食症的改善，动力和力量的希望。伊甸园项目旨在调查氯胺酮在60名成年人中抑郁症的影响，并诊断出持久性厌食和治疗抑郁症。该研究的参与者将每周两次随机接受氯胺酮或虚拟药，总共六个月。为了验证该药物是可以忍受的，将在伦敦国王学院的临床研究机构中给予前四剂，在那里参与者将受到医疗专业人员的监视。此后，如果耐受性良好，参与者可以将药物带回家。所有参与者还将获得十个“心理教育和整合”会议，旨在增加氯胺酮的有益作用。主要结果将研究是否在研究期间招募了足够数量的人，并且没有辍学，并且人们是否找到了该药物，以及可以接受研究本身。抑郁症，厌食症症状，自杀性和生活质量的测量将在28天以及3日，6个月和7个月后进行。还将采集血液样本，以查看氯胺酮的水平。